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Life is really simple, but we insist on making it complicated 
 
 
Confucius 
 
ABSTRACT 
 
Breast cancer (BC) exhibits great heterogeneity at histophatological, clinical and 
molecular levels. However, the different clinical outcomes in patients with seemingly 
similar breast cancer have led scientists to search for subgroups or for factors and 
characteristics related to the tumor or the patient that could anticipate clinical course 
(prognosis) of disease and/or response to given therapy (prediction). Estrogen receptor 
(ER) is the first molecule identified that has had great influence on the management of 
breast cancer. This thesis focuses on the role of ER and its significance in breast cancer.  
 
In one study, we compared the potential of ER-positive tamoxifen sensitive cells 
(MCF-7) versus ER- negative cells (MDA-231) to handle DNA repair, transmit signals 
from DNA damage, initiate apoptosis, control transmitted signals from the cell cycle 
and synthesize growth factors and receptors. Genes related to these processes were 
studied by cDNA microarray.  We found that the ER-negative cells were characterized 
by a higher expression of growth factors and cell cycle regulation components, and 
improved DNA repair.  
 
We explored the long-term pattern of disease recurrence among pre-and post-
menopausal patients with primary BC according to ER status. The patients were 
randomly given tamoxifen versus no systemic therapy. The results showed a reduction 
of locoregional, distant metastases and breast cancer death in ER-positive patients who 
received tamoxifen. The pattern of metastases was not different in these two groups. 
The conclusion was that the differences in term of gene expression appeared mainly to 
be related to endocrine sensitivity and not metastatic potential. Some more events in the 
first 5 years in ER-negative patients suggested that ER negativity in some cases is 
correlated with an increased tumour growth rate. 
 
ER had been measured by cytosol assays prior to around 1990 when these assays 
substituted of immunohistochemical (IHC) assay. However, ER predictive ability of 
response to tamoxifen has been assessed based on ER measurement by cytosol assays. 
We compared these two assays in a clinical trial and found a high concordance between 
the assays and concluded that IHC is as accurate as cytosol assays to predict long term 
response to adjuvant tamoxifen. 
 
The introduction of microarray technique a decade ago already has changed our 
knowledge of BC but it has some pitfalls that question its potential. In two methodical 
studies we showed the importance of tissue handling, the effect of heterogeneity of BC 
and standardization on the result from cDNA microarray. 
 
This thesis confirms the importance of ER in BC but also indicates a more complex 
phenotypic beyond that which can be explained purely by ER content or endocrine 
sensitivity. Microarray technique can provide useful information besides the traditional 
one but requires standardization of sample collection, storage, processing, 
normalization, interpretation of data and requires validation by large studies.  
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1 GENERAL INTRODUCTION 
 
Breast cancer (BC) is the most frequent malignancy in women and is a leading cause of 
death in women in Europe and North America. The incidence rate of BC has been 
increasing with more than one million cases of invasive breast cancer (IBC) being 
diagnosed worldwide every year. However, the mortality from BC has remained 
unchanged during last 3 decades[2] mainly due to an early detection and more effective 
therapies.  
 
BC is a multifaceted disease and shows substantial heterogeneity at histophatological, 
clinical and molecular levels. With the knowledge of this heterogeneity, intensive 
efforts have been made to find some relationship between clinical characteristics and 
underpinning histopathological as well as molecular features. The classification of BC 
into subtypes and identification of prognostic and predictive factors are results from 
these efforts. Even if, a great improvement in the management of BC has been 
achieved, the vision in management of patients with BC is to offer them an individual-
based treatment plan to avoid over and under treatments that can cause unnecessary 
morbidity and mortality. Estrogen receptor (ER) that was discovered in 1962 [3], 
become the first molecule with great influence on the treatment of IBC. Since the 
discovery of ER and later progesterone (PR), intensive research has been concluded on 
the role and significance of hormone receptors, particularly ER in tumorogensis, 
progression, metastasis, prevention and the treatment of BC.  
 
About two third of post-menopausal and approximately half of pre-menopausal women 
with invasive breast cancer have an ER-positive and/or PR-positive breast cancer. 
Surgery remains as the primary treatment for the majority of non-metastatic BC, whilst, 
radiotherapy, endocrine therapy; chemotherapy and biological therapy have become an 
essential part of breast cancer management both as adjuvant and in metastatic diseases. 
Ovarian ablation is the first form of systemic therapy for the endocrine treatment of 
BC, originally described at the end of the nineteenth century for the treatment of 
inoperable disease in Premenopausal women [4], long time before the identification of 
estrogen and ER. In 1936, Antoine Lacassagne discovered estrogen as the agent in 
ovaries that caused BC[5]. 1962, ER was identified by Jensen and Jacobson [3] who 
subsequently correlated the presence of ER with the hormone responsiveness of tumor 
in BC [6]. Tamoxifen was discovered in the mid 1960s and was initially used in 
advanced BC[7]. Tamoxifen was approved for endocrine therapy of advanced BC in 
the United Kingdom in 1973and in the United States in 1977[8]. Since then a large 
body of evidence has shown the effect of tamoxifen in endocrine sensitive breast 
tumours.  Development of aromatase inhibitors has further improved effectiveness of 
endocrine therapy. However, in patients with estrogen receptor (ER)-positive disease, 
only 50-60% of the patients receive clinical benefit from these agents. Furthermore, the 
vast majority of patients develop resistance to all form of endocrine therapy within few 
years. 
 
There are a number of important questions about endocrine therapy, which concern 
researchers today. These include:  
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1. Why do not all hormone positive breast cancer patients respond to endocrine 
therapy?  
2.  Among those with an initial good response, why does this response decrease or 
become totally irresponsive?  
3.  What is the molecular mechanism for the development of this resistance?  
4.  What is the exact mechanism of ER in the development of BC?  
5.  What is the role of ER in the prevention of BC?   
 
Several different mechanisms for resistance development have been suggested, such as 
a decreased level of, or lack of ER, a reduced intracellular level of tamoxifen and 
upregulation of growth factors. Changes in the balance of co-activators/co-repressors 
leading to the regulation of the antagonist/agonist action of anti-estrogens are now the 
focus for investigations.    
 
ER is a transcription factor, which stimulates proliferation and differentiation of normal 
breast epithelial cells and cancer cells. The human ER mRNA is transcribed from a 
complex gene. The exact molecular mechanisms regulating ER expression in BC are 
unclear. The microarray implement makes it possible to study the mechanism of action 
and resistance of ER on the genes levels. 
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Figure 1.Incidence and mortality in different 
regions[1].Estimated ASR (world) per 100,000 
 
1.1 EPIDEMIOLOGY OF BREAST CANCER 
 
1.1.1 Breast cancer incidence 
 
Cancer of the breast in 
females is the most frequent 
malignancy among women 
worldwide. It accounted for 
23% of all cancers cases  
diagnosed in 2002 and took 
overall second place when 
both sexes were considered 
together[2]. Hence, BC is 
responsible for more than 
one million cases of the 
estimated 10 million 
malignancies diagnosed 
each year in both sexes [9]. 
Furthermore,  BC is  the 
primary cause of cancer 
death among women 
globally, responsible for 
about 375000 deaths in the 
year 2000 [9]. The 
incidence of BC varies 
extensively in different parts of the world, because of dissimilarity in life style and  
occurrences of many known risk factors [10] (Figure 1).The highest incidence occurs in 
developed areas such North America, Northern and Western Europe, Australia and 
New Zealand, whereas the incidence is low in Africa and Asia [11]. In developing 
countries the available cancer data indicates that the incidence of BC increases most 
likely as a consequence of following Western lifestyles [2, 12]. In China, the incidence 
of BC started to increase in socially and economically well-developed regions , 
becoming the number one type of malignancy in women[13]. The geographical and 
temporal variation in BC incidence rate can be explained by changes in the risk factors. 
The high rate of BC in western countries is due to a higher prevalence of the well-
known risk factors for BC, such as early age at menarche, null or low parity, late age at 
any birth and late menopause, i.e estrogen related factors [14]. On the other hand, the 
higher parity and early age at first pregnancy in many developing countries might 
account for much of the lower incidence. The other explanation is long-standing breast 
feeding in these countries that shows a protective role[15]. Furthermore, exposure to 
exogenous hormones such as oral contraceptives[16] and hormone replacement 
therapy[15] results in an increase in the risk of BC. 
 In Sweden, approximately 7,300 cases of BC in females were diagnosed in 2008. 
Breast cancer is the most common cancer in women and encompasses nearly 30% of all 
malignancy in women (The National Board of Health and Welfare, 2008). The 
incidence rate of BC in Sweden was 84/100,000 women in 1974, increasing to 
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157/100,000 women in 2008 (figure 
2).  In other world, the incidence has 
increased by 1.2% per annum during 
the last 20 years, although the rate of 
increase has been slower during the 
latter 10-years with an average 
annual change of 0.8%t (The 
National Board of Health and 
Welfare, 2008). 
 
 
 
 
1.1.2   Breast cancer mortality 
Breast cancer mortality in most European countries increased from the 1950s until the 
1980s when it became stable and declined since [17, 18] (Figure 3). The same trend has 
been observed in North America[19], however,  no decrease has been shown for Black 
American women[20]. Mammographic screening has resulted in early detection of BC, 
which together with more individual awareness and more aggressive and effective 
treatment in recent years, accounts for the reduction in mortality in these countries. The 
mortality from BC in developing countries is higher than the mortality in developed 
countries due in part to lack of widespread mammographic screening and lesser 
aggressive treatment. Byers at al, reported that low socioeconomic status was 
associated with more advanced disease stage and with less aggressive treatment for 
breast, prostate and colorectal cancer in USA [21].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Sweden, about 1500 women have died from BC each year in previous decades. 
However, breast cancer mortality- in contrast to incidence- has been stable since 1960s 
and started decreasing since the 1980s. The estimated annual reduction in the last ten 
years has been approximately 1.5% per year. 
 
Figure 3.Mortality in North Europe[1]. Age-standardized rate (W) 
per 100,000. 
 
Figure 2.Breast cancer incidence, 
number cases per 100,000. 
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1.2 HISTOLOGICAL AND MOLECULAR TYPES  
Breast cancer is a complex disease, consisting of several subgroups that show different 
clinical activity and biological features [22-24]. The histopathological heterogeneity of 
BC has long been illustrated by histopathologists who have attempted to classify BC 
into meaningful distinct subgroups [25-27]. During last decade microarray-based 
studies have identified multiple molecular subtypes [28-31]that broaden the idea of 
heterogeneity of breast carcinoma. 
 
1.2.1 Histological types 
Histopathological examinations have revealed specific architectural and cytological 
patterns that are almost always associated with typical clinical manifestation as well as 
prognosis in breast cancer. These “ histological special types” account for up to 25% of 
all BC[32]. The latest edition of the WHO classification of BCs discriminates the 
existence of at least 17 different histological special types[32]. However, the vast 
majority (50-80%) of BCs are called invasive ductal carcinomas not otherwise 
specified (IDC-NOS) or of no special type (IDC-NST). This means that majority of BC 
have not sufficient architectural and cytological characteristics to be classified into one 
of the special types and show variations in clinical features and outcomes.  Even if,  the 
special subtypes of BC have distinct morphological and clinical features and prognostic 
implications [32], the use of information on histological types have been limited in 
clinical practice management of patients with BC. This is because of the lack of 
standardized criteria and low interobserver reproductibility for diagnosis of special 
type[33]. Furthermore, special histological types of BC have been mainly neglected in 
studies of microarray-based molecular classification class discovery[28-31] and class 
prediction[34-38].The 2003 WHO classification gives an accurate definition of IDC-
NST, pure and mixed types of breast cancer[32]. 
Conventionally, invasive human breast carcinomas have been classified 
morphologically into ductal and lobular carcinoma, tubular carcinoma, mucinous 
carcinoma, medullary carcinoma, invasive papillary carcinoma, metaplastic carcinoma 
and some uncommon types. For a long time, it was supposed that special histological 
types of BC arise from distinct microanatomical structures of the normal breast, hence 
the terminology of ductal and lobular carcinoma. The influential work by Wellings et al 
however, showed the vast majority of invasive breast cancer and their in situ 
precursors, initiate from the terminal duct lobular unit regardless of histological type 
[39, 40]. Thus, the terms ductal or lobular carcinoma do not imply site of origin or 
histogenesis, rather these entities are defined on the basis of their architectural patterns, 
cytological features and immunohistochemical profiles[33]. 
  
1.2.1.1 Invasive ductal carcinoma 
Invasive ductal cancer is the most frequent BC and accounts for two thirds of all BC. 
Microscopically, it is characterized by variably thick strands of more than one cell 
layer, often with tubule formation (Usually with grade II/III nuclei). It sometimes forms 
solid tumor nodules with central sclerosis, necrosis and with DCIS. With palpation it is 
stony hard [41]. Tumors with stellate arrangement and focal necrosis have a 
particularly poor prognosis. This cancer typically metastasizes to bone, lung and liver. 
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1.2.1.2 Invasive lobular carcinoma 
This type includes only 5-10% of BC and is characterized by ill-defined thickening or 
induration in the breast. Microscopically, it is composed of small cells in a linear 
arrangement (Indian File) with a tendency to grow around ducts and lobules. Compared 
to IDC, it has a greater proportion of multicentric tumors. This type is cell-poor and 
more often spreads to meninges, serosal surfaces, ovaries and retroperitoneum.  
 
1.2.1.3 Tubular carcinoma 
Tubular carcinoma is a variant of infiltrating ductal cancer that is usually detected by 
mammography. This type comprises about 5 % of all BC. Microscopically, more than 
75% of tumors are composed of simple, well-formed tubules lined by single layers of 
cells. It shows low nuclear grade and has better prognosis than IDC. It is often is ER 
and PR- positive.  
 
1.2.1.4 Medullary carcinoma 
About 5-7% of all BC are of this type, which is more common in younger women (<50 
years old). Patients may have enlargement of axillary lymph nodes, even in the absence 
of nodal metastases. This type is characterized microscopically by sheets of tumor cells, 
poorly differentiated nuclei, severe infiltration of small lymphocytes and plasma cells. 
There is usually no associated DCIS or just a little DCIS. Typical medullary BC has 
better prognosis than IDC but atypical medullary has the same prognosis.  
Medullary cancer is typically ER-negative, PR-negative, HER-2 negative and usually 
p53 positive, indicating p53 mutation. 
 
1.2.1.5 Papillary carcinoma 
This type of BC is uncommon and accounts for about 1-2% of all BC.  Papillary BC 
usually occurs in older women and is multifocal. It is normally ER-positive and shows 
good prognosis.  
 
1.2.1.6 Mucinous carcinoma 
Mucinous BC is characterized by rich accumulation of extracellular mucin around 
groups of tumor cells. This tumor type grows slowly and can become large and bulky. 
About 3% of all BC is of this type and when the tumor is mainly mucinous the 
prognosis tends to be good. However, mucinous BC with lymph nodes involvement has 
worse prognosis; about 76% 5 year Disease Free Survival (DFS)[42] . Cerebral 
infarction due to mucin embolism is an unusual complication in patients with mucinous 
breast cancer.  
 
1.2.2 Molecular types 
Normal mammary glands consist of two layers of cells: a well-differentiated inner 
(luminal) epithelial layer and an outer layer along the basement membrane. These cell 
types can be distinguished by the expression of certain cellular markers. Gene 
expression profiling by cDNA microarray and hierarchal clustering analysis has 
identified several molecular subgroups within BC. By analyzing gene expression of 
115 breast tumor samples, Sorlie et al showed 5 subtypes: two ER-positive subtypes 
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(luminal A and luminal B) and three ER-negative subtypes (HER-2 enriched, basal-
like, and breast-like)[29, 30, 43]. The molecular subtypes can prognosticate clinical 
outcomes like recurrence free survival and overall survival [30]. Furthermore, these 
subtypes are constantly present despite systemic therapy and appear to remain 
concordant during the metastatic process [31, 44, 45]. 
 
1.2.2.1 Luminal A 
Luminal type A comprises the most cases of BC (56-61%) , is characterized by high 
levels of ER expression and is associated with relatively good prognosis[46]. The 
typical immunohistochemical profile of luminal type A is ER-positive and/or PR 
positive, and HER 2 negative. Based on the molecular profile, all cases with pure 
lobular carcinoma in situ (LCIS) are luminal type A tumors [47]. Consequently, the 
large majority of invasive lobular carcinoma have a profile characteristic for luminal A 
type[48]. Luminal A tumors show conflicting  gene expression profile and have very 
variable prognostic signatures[43]. 
 
1.2.2.2 Luminal B 
Luminal type B (9-16% of cases) tumours might present a more aggressive phenotype 
than luminal A and include tumors with high histological grade [29].  In contrast to 
luminal A, this tumor type is more frequent. They show HER2, EGF1, cyclin E1, ER 
and/or PR [30, 49]. 
 
1.2.2.3 Basal-like breast cancer (BLBC) 
This subtype is characterized by the presence of myoepithelial cells that express CK 
5/6, CK 14, CK17, vimentin, EGFR, and have a high proliferation index[50]. This 
group of BC typically lacks the CKs seen in the luminal groups and is often ER and PR 
negative. Morphology of basal-like BC is not typical and overlaps with many other 
subtypes. However, basal-like BC is mostly infiltrating ductal carcinoma with solid 
growth pattern and high nuclear and histological grade. Furthermore, other 
morphological types like atypical medullary carcinoma can be of basal-like type [51, 
52]. They were named basal-like, before the era of gene microarray profiling, because 
of their expression of basal CKs, such as CK14 and CK17 [53, 54]. Basal-like BC is 
negative for ER, PR, and HER-2 [53, 55] . HER-1 is positive between 45 to 75 % of 
basal-like BC [53-57].  P53 gene mutations have been observed in about half of cases 
[53, 57, 58] and high Ki67 index in 67% of cases [58]of basal-like BC. There is no 
general consensus on the immunophenotypic criteria of basal-like BC. Therefore a 
standardized criterion that may facilitate further study on this group of tumor is 
necessary. The correlation between basal-like BC and clinical outcome has been 
studied; most studies provided evidence that basal-like BC is associated with a worse 
clinical outcome than other subtypes of BC [30, 44, 56]. Basal-like BC is more frequent 
in premenopausal Black women, where the incidence rate is 39% compared to 14 % in 
postmenopausal Black women and 16 % in non-Black women of all ages [59]. 
Additional studies have confirmed that basal-like tumors are more frequent in young 
women [47, 60]. These tumors tended to have aggressive features including high 
nuclear grade, high mitotic index, and unfavorable histology. Strangely enough, this 
subtype was not associated with higher regional lymph node involvement. 
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Disconnection between tumor size and positive lymph nodes have been shown in this 
subtype of BC by several studies [61, 62].  
 
1.2.2.4 HER-2 enriched 
This subtype (8-16%) is characterized by high expression of HER-2-related and 
proliferation genes and low expression of hormone receptor-related genes [30, 31, 44]. 
The HER-2 type BC based on the expression of ER, splits in two distinct subtypes: an 
ER-negative subtype which is closer to the basal-like subtype and  an ER positive  
subtype that is closer to the luminal B tumors[48].  Immunohistochemical profile of 
HER-2 enriched tumors is ER negative, PR negative, HER-2 positive, EGFR focal 
positive, CK5 negative and CK 8/18 heterogeneous and moderate positive[48].  HER-2 
type is often associated with ductal cancer in situ (DCIS). Many of these cases are less 
differentiated and have poor prognosis [63] 
 
1.2.2.5 Breast like 
About 6-10% of BCs are of this subtype.  This type is a triple negative tumor and is 
close to basal-like tumors in terms of molecular profile. These tumors have a slightly 
better prognosis than basal-like tumors. The immunohistochemical profile of these 
tumors was shown negative for ER, PR, HER-2, CK5 and EGFR. 
 
1.3 PROGNOSTIC AND PREDICTIVE FACTORS 
1.3.1  Prognostic factors 
A prognostic factor is any factor with ability to provide information on the clinical 
outcome in untreated patients at the time of diagnosis. Thus, prognostic factors help 
decision making to separate patients with breast cancer who need adjuvant treatment 
from those who do not need therapy. Several tumor specific and patient specific 
prognostic factors have been identified. Unfortunately, even using a combination of 
these factors can not anticipate the outcome of disease in an individual patient. It should 
be mention that these factors play an informative role in a group of patients. The 
microarray based gene expression profile has been used to identify a prognostic 
signature with potential to give information on the clinical outcome in an individual 
patient. The current trend is to combine the conventionally prognostic factors and genes 
array based signatures to make decision on treatment plan. In our institution we have 
used age, tumor size, lymph node status, ER status, tumour grade, ki 67 and HER2 
overexpression/amplification to make therapy recommendations. 
 
1.3.1.1 Age 
Several studies have indicated that age at the time of diagnosis has prognostic value 
with a worse prognosis in young patients [64-67]. Although, this less favorable 
prognosis in younger women can at least to some extent, be a reflection of higher risk 
for lymph nodes metastasis, ER-negativity and larger tumor in young patients [68, 69]. 
On the other hand, some studies have shown a negative effect of age even after 
adjusting for the confounding factors [70-72]. Furthermore, some investigators have 
shown that BLBC which has poorer prognosis is more frequent in young women [47, 
60]. Our local therapy guidelines for treatment of BC at Karolinska University Hospital 
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make a distinction between ages under and over 40 because of the high risk of 
unfavorable outcome in the younger ages. 
 
1.3.1.2  Tumor size 
The size of primary tumor together with the number of lymph nodes involved has been 
considered as a powerful prognostic factor and has had major impact on treatment 
decision making. Tumor size has positive correlation with odds of nodal 
involvement[73]. In a study of node negative BC, patients without adjuvant treatment 
and tumor size smaller than 20 mm had a 20 year DFS of 79% whereas patients with 
tumors larger than 20 mm had a 20 year DFS of 64%[74]. In 767 breast cancer patients 
with staging T1/T2, LN-negative at the time of surgery who received neither radiation 
nor adjuvant therapy and more than two decades follow up having the tumor of 10 mm 
or less in diameter, had a 88% RFS at 20 years[75]. 
 
1.3.1.3 Lymph nodes status 
Axillary lymph node (ALN) metastasis is a strong prognostic factor in breast cancer 
with poorer prognosis as the number of ALN metastases increases[76]. Patients with no 
ALN metastasis have about 20% risk of recurrence at 5 years and their 10 year survival 
is 65-80%, while, patients with more than 4 ALN metastases have 54-82% relapse risk 
at 5 years and their 10 year survival is 13-24% [76, 77]. About 10-20% of cases with 
LN-negative BC on histopathological examination may be diagnosed LN-positive by 
use of monoclonal antibodies. The prognostic value of micro (0.2-2mm) and especially 
submicrometastasis (<0.2 mm) is being discussed. However, using sentinel node 
procedure and an intensive examination of these nodes have resulted in an increased 
detection of ALN metastasis even if the majority of these metastases are small 
including isolated cells and micrometastases [78]. De Boer at al in a meta-analysis 
showed that the present of metastases of 2 mm or less in size in ALN was associated 
with poorer DFS and OS[79]. The American Joint Committee on Cancer (AJCC) and 
WHO classifications according to size, LN involvement and distant metastasis (TNM 
staging system)( table 1)have become the most important prognostic tools in breast 
cancer[80]. However, some aspect of this classification has been questioned [81]. 
 
1.3.1.4 Histological grade 
Histologic grade is determined as part of the diagnostic microscopic examination. The  
histologic grading according to Elston and Ellis which is a modification of histologic 
grading that was originally presented by Bloom and Richardson, is the most frequently 
used system [82, 83]. This grading involves semiquantitative evaluation of three 
morphological features, percentage of tumor area with tubule formation, nuclear 
pleomorphism, and number of mitotic counts per defined microscopic field area. The 
prognostic ability of histologic grading has been discussed.  Some investigators 
reported a strong connection to prognosis[83] but others were unable to show that the 
grade is of prognostic significance[84]. Furthermore, its reproducibility between 
laboratories has been questioned[85]. 
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Table 1.TNM staging system and corresponding survival according AJCC WHO. 
 
Stage TNM grouping Overall survival* 
T N M 5 year% 10 year% 
0 Tis N0 M0   
1 T1 N0 M0 87 78 
II A T0 N1 M0 68 52 
T1 N1 Mo 
T2 N0 M0 
II B T2 N1 M0 
T3 N0 M0 
III A T0 N2 M0 41 28 
T1 N2 M0 
T2 N2 M0 
T3 N1-2 M0 
III B T4 N0-2 M0 
III C Any N3 M0 
IV Any Any M1 10 0 
T=tumor size, N=nodal status, M=distant metastasis. *American Joint Committee on 
Cancer (AJCC) Cancer Staging Manual, ID Fleming (ED) Lippincott-Raven,1997 
 
 
1.3.1.5 Estrogen and progesterone receptor 
Two human ER have been determined, ERα and ERβ. ERα was named ER up to the 
discovery of ERβ, consequently all data on prognostic and predictive capacity of ER is 
relevant for ERα. In addition, in breast cancer ERα is in the majority [86], so ERα is 
more relevant to previous finding. There are conflicting reports regarding the 
prognostic significance of ERα status in early stage BC. Many early studies reported a 
more favorable prognosis for patients with ERα-positive tumors suggesting that ERα 
status was an independent prognosticator [87-90]. However, later studies indicated that 
the early advantages for ERα-positive BC were not sustained at longer follow-up [91-
93]. The conflicting results are probably due to small studies, lack of standard cutoff 
point for hormone receptors, short follow-up and finally lack of control of relevant 
other prognostic factors including use of adjuvant tamoxifen. Our results ( paper 4) 
indicated that ER has no or frail prognostic ability but strong predictive ability for 
respond to endocrine therapy. The overview of all available trials of adjuvant tamoxifen 
showed a significant improvement of both RFS and OS with tamoxifen in ERα-positive 
patients. In contrast, no clinically worthwhile treatment benefit was observed in patients 
whose tumors were classified as ER-negative[94]. The progesterone receptor consists 
of two isoforms, PR-A and PR-B. progesterone receptor is ER regulated and mediates 
the effect of progesterone in both normal mammary gland and BC[95]. It reported that 
a ratio of PR-A/PR-B has confirmed significant for normal development of the 
mammary glands in rodents [96] and an increased PR-A/PR-B ratio has been described 
in BC [97]and may be associated with resistance to tamoxifen[98]. 
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1.3.1.6 HER2-neu (ERBB2) 
HER 2 gene is a member of the epidermal growth factor receptor (EGFR) family that is 
located on chromosome 17q21. The protein encoded by this gene is a transmembrane 
tyrosine kinase growth factor receptor. All epithelial cells express 20,000-50,000 HER2 
receptors on their cell surface. However, cells that over express HER2, express 
receptors numbering in the millions. There is no known ligand, but they form 
heterodimers with the other family members and; cause kinase-mediated activation of 
downstream signaling pathways. Over-expression is associated with poor prognosis and 
occurs most frequently by amplification.[99-101]. It is rarely expressed in lobular 
carcinoma but always overexpressed in inflammatory  BC[101]. HER2 is both a 
prognostic and predictive factor.  Amplification determined by FISH and recently by 
CISH or IHC determination of protein by IHC is assessed in clinical routine to choose 
patients suitable for trastuzumab treatment [102]. Furthermore, it has been suggested to 
have treatment predictive capacity for anthracycline, aromatase inhibitors and 
tamoxifen. 
 
1.3.1.7 Proliferation rate 
The proliferation rate of breast cancer cells has been recognized as a marker for both 
prognosis and tumor response [103-105]. The cell-proliferation rate can be assessed by 
synthesis phase fraction (SPF) using flow cytometry, mitotic index (MI) and Ki67 
(MIB1) using immunostaining. There is no consensus on which assessment is more 
precise due to inconsistent results. Differences in methodology should account, at least 
in part, for these discrepancies. MIB1 has been analyzed in several breast cancer 
studies and found to provide significant prognostic information [106-108], whereas a 
better discriminative value was reported by others for MI [104, 109, 110] or SPF[111]. 
In our institution, the current assessment of proliferation rate uses Ki67 (MIB1) by IHC 
assay and has substituted SPF which was commonly used up to the late nineties. For 
instance, based on reports, the median value of MIB1 in breast carcinoma was reported 
to be less than 10%,[112, 113] between 10-20% [114, 115]and over 20%[107, 108, 
116]. These differences in reporting the median value of MIB1 indicate the importance 
of standardization of methodology to be used for MIB1 assessment. Thymidine Kinase 
1 (TK1), an enzyme closely related to DNA-synthesis and thus a marker for 
proliferation, has recently been compared to Ki67 in breast cancer studies and found to 
give higher positive rate than Ki67[117]. Cytosolic Thymidine kinase is a specific 
histopathologic tumor marker for breast carcinomas [117]. TK1 expression in atypical 
ductal hyperplasia significantly differs from ductal hyperplasia and DCIS; considering 
to be a useful tool in tumor therapy management[118].  
 
1.3.1.8 Other prognostic factors 
Several other factors, such as P53, angiogenesis, bone marrow micrometastases 
(BMM), cathepsin D and many more, have been suggested and discussed as 
prognosticator but their used in daily clinic practice very limited if any. It should 
mention that each individual factor has limited clinical value but considering these 
factors in combination are of greater value. However, current trends in oncology is 
analyzing  tumor samples with a panel of genes using gene expression profile or the 
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genes surrogate protein using IHC technique to make diagnosis or determine prognosis 
and predictive ability to a candidate treatment.   
 
1.3.2 Combined prognosis and predictive approach 
1.3.2.1 St Gallen criteria 
According the St Gallen criteria[119] and including age, tumor size, lymph node status, 
histological grade,HER2-neu and peritumoral vascular invasion in risk calculation, 
patients with operable breast cancer are divided in three risk groups ( table 2). Notably, 
for the first time, the hormone status is not included in risk category. 
 
Table 2.St Gallen risk criteria; Adapted from Goldhirsch et al. Ann Oncol 2005; 16: 
1569-158. 
Low risk Intermediate risk High risk 
LN- negative + all of the following 
•pT <2cm 
 •grade 1 
•No peritumoral vascular invasion 
•HER2/neu negative 
•Age≥35 years 
LN-negative+ at least one of 
•the following 
•pT>20mm 
•grade 2-3 
•peritumoral vascular invasion 
•HER2/neu positive 
•Age<35 years 
LN-positive  
1-3 nodes plus 
•HER2/neu 
positive 
LN-positive 1-3 plus 
•HER2/neu negative 
LN>4 nodes 
 
 
1.3.2.2 Nottingham Prognostic Index. 
The Nottingham Prognostic Index (NPI) combines three prognostic factors: nodal 
status, tumor size and histological grade. NPI is not applied in patients with metastatic 
disease. For NPI, three categories of LN status are used: stage 1 no lymph node 
metastasis, stage 2, up to 3 low axillary LN involvements or internal mammary node ( 
assessed in medially located tumors) and stage 3, more than 3 low axillary LN 
metastases and/or the apical axillary node or of both low axillary and internal 
mammary nodes. All tumor deposits of 0.2 mm and above are regarded as LN 
metastasis. Tumor size is based on measurement of the invasive component in 
histological section. The third factor, histological grade is based on Nottingham 
modification of the Scarff-Bloom-Richardson method of assessing histological grade. 
The index is calculated by this formula: NPI=lymph node stage (1-3)+histological 
grade (1-3) + tumor size (cm) x o.2[120]. The NPI has been validated by further studies 
in Nottingham and by studies from several other countries [121, 122]. In NPI several 
important factors, such as HER2/neu, age and; peritumoral vascular invasion are not 
included. 
 
1.3.2.3 Adjuvant Online (www.adjuvantonline.com) 
Adjuvant! Online is an evidence based computer program which has designed to make 
information in the San Antonio Data Base more relevant to clinical practice. The 
program is based on information from the SEER data base, the overviews of clinical 
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trials, individual clinical trial results, and the literature in general. The basic format of 
an early version of Adjuvant! was described by Ravdin et al [123]. There are currently 
3 different versions of adjuvant! For BC: adjuvant (standard), adjuvant after 5 years of 
tamoxifen, and adjuvant genomic version. The factors includes in adjuvant! are: age, 
performance status, ER status, tumor size, histological grade and nodal status. The 
results indicate survival chance and suggest treatment recommendation. 
 
1.3.3 Multigene tumor assays 
1.3.3.1 Oncotype DX 
OncotypeDX is an RT-PCR-based assay from Genomic Health that can be performed 
on formalin-fixed tissue from paraffin blocks. It is based on analyses of gene 
expression profiles of 21 genes (16 cancer-related genes including genes related to ER, 
PR, HER2, proliferation and invasion and 5 control genes) and provides a “recurrence 
score (RS)” that correlates with outcome, as well as probability of response to 
endocrine therapy and chemotherapy [124-127]. Oncotype DX recurrence score 
provides a prognosis for patients with ER-positive BC treated with tamoxifen alone 
[125]. In one study, the recurrence score predicted benefit from CMF chemotherapy 
[126]. Although, patients with low RS have not benefited from chemotherapy added to 
tamoxifen, patients with high RS seemed to benefit from the addition of chemotherapy 
to tamoxifen. Albain et al reported that the RS is even prognostic for tamoxifen-treated 
node positive patients and predicts significant benefit of anthracycline based 
chemotherapy (CAF) in tumors with high RS.  A low RS identifies women who might 
not benefit from chemotherapy, despite positive nodes [128]. Use of RS as a prognostic 
and predictive tool in ER-positive lymph node negative breast cancer was 
recommended by the American Society of Clinical Oncology [129]. The usefulness of 
Oncotype DX will be assessed in an ongoing large prospective trial, TAILORx 
trial[127]. 
 
1.3.3.2 Mammaprint 
Mammaprint from “Agendia” uses expression array analysis of 70 genes to identify 
patients with good and poor prognostic signatures [35, 130, 131]. The prognostic value 
of this gene signature was confirmed in a study of 295 patients who were classified as 
having good and poor prognosis. The results showed the gene signature to be a more 
powerful predictor of disease outcome than conventionally used factors based on 
clinical and histological criteria [35]. The prognostic value of Mammaprint has been 
independently confirmed [132].This assay requires fresh frozen tumor tissue. This 
assay are already being used in patient management, but its ultimate worth will be 
determined by the results of a prospective clinical trial that currently started, the 
MINDACT (Microarray In Node-negative Disease may Avoid ChemoTherapy) trial 
[131].  
 
1.3.3.3 Other multigenic test 
 
Several multigene assays are either in development or on the market but are not 
approved. These tests and their characteristic shows in table 3.  
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Table 3.Prognostic and predictive test based on gene array or IHC and their using 
area. 
Test Gene 
or 
protein 
Method Sample 
conditions 
Prognostic 
established 
Guide to 
therapy 
Mammostrat 5 IHC FFPE No Tamoxifen 
eXagenBC 3 FISH FFPE No No 
Invasivenesssignature 186 Microarray Fresh7frozen Yes No 
Molecular portraits 50 Microarray 
RT-PCR 
Fresh/frozen Yes Neoadjuvant 
chmotherapy 
Theros Two-gene 
Ratio 
6 RT-PCR FFPE No  Tamoxifen 
Celera Metastasis 
Test 
14 RT-PCR FFPE No Tamoxifen 
Rotterdam Signature 76 Microarray Fresh/frozen Yes Tamoxifen? 
NuvoSelect 200 Microarray Fresh/frozen No Neoadjuvant 
TFAC, 
tamoxifen 
FFPE:formalin-fixed,paraffin-embedded.RT-PCR:reverse transcriptase PCR. 
TFAC:paclitaxel,fluorouracil,adriamycin,cyclophosphamid 
 
1.3.4 Predictive factors 
Any factor that can predict the effect of certain treatment is a predictive factor. Thus, a 
predictive factor indicates if the treatment has benefit. Several predictors have been 
identified in breast cancer and suggest the basis for some of the current systemic 
therapies. 
 
1.3.4.1 ER and PR  
The most known predictive factor is ER status which predicts the effect of endocrine 
therapy. The predictive value of PR is not clear but its co-expression with ER; raises 
the probability of endocrine responsiveness in ER-positive BC.  
 
1.3.4.2 HER-2 
The overexpression / amplification of HER-2 indicates the usefulness of trastuzumab 
treatment. In daily clinical practice, the amplification of HER-2 provides the basis for 
selecting patients who will benefit from trastuzumab treatment.  
 
1.3.4.3 Proliferation rate 
Proliferation rate has been correlated to sensitivity to chemotherapy [103, 133] and 
high proliferation rate may well support chemotherapy. On the other hand, proliferation 
rate measured by the means Ki67 is related to outcomes. TK1 is another marker for 
proliferation and its level in serum also predicts relapse within 3 months after surgery 
[134]. 
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1.4 ESTROGEN RECEPTOR 
A majority of human BCs are primarily positive for ERα, and their growth can be 
stimulated by estrogen and inhibited by antiestrogen [135, 136]. The presence of ER in 
target tissue or cell is essential to their responsiveness to estrogen action. The cloning 
of ERβ [137-139] and its high sequence homology to ERα [137, 138] have complicated 
the mechanisms of breast carcinogenesis of estrogen. ER β can be inhibited by 
antiesrtrogens and stimulated with estrogen[140] and can form homodimers as well as 
heterodimers with ER α[140-142]. Thus, the existence of two ER subtypes and their 
ability to form DNA-binding heterodimerers suggests three potential pathways of 
estrogen signaling; via ERα and ER β homodimers and via the formation of 
heterodimers of ER α   and ER β in tissue that express both receptor types [140]. 
 
1.4.1 Estrogen receptors structure 
Human ERα is a protein consisting of 595 amino acids. It is divided into six separate 
regions, named A to F and includes at least five functional domains. The domain 
located in amino-terminal shows a vast variation in both length and sequence and 
contains a hormone-independent transcription activation function (AF-1). AF-1 can 
stimulate transcription in the absence of hormone binding and is thought to be 
responsible for gene and cell specificity [143-146]. AF-1 is also important for the 
agonist activity of mixed antiestrogens [147]. It has therefore been suggested that the 
AF-1 domain may play a role in hormone resistant breast cancer [148, 149]. The DNA 
binding domain is extremely preserved among the nuclear receptors super family 
(including ER). Hormone binding to receptors induces conformational changes in the 
ligand-receptor complex that allow the receptor to fasten to the estrogen-responsive 
element within target genes [150-152] and activate the target genes. The next domain 
within ER, the hinge domain, allows ER to rotate. Furthermore it may be an important 
site for binding of accessory proteins [153]. A nuclear localization signal resides in this 
domain is responsible for the nuclear localization of ER. The ligand-binding domain is 
where the ligand binds to receptor into a “binding pocket”. Structural studies of the ER 
ligand-binding domain indicate that the “binding pocket” for the ligand is nearly twice 
the volume of its estrogen ligand. This difference might help explain the high affinity of 
synthetic ER ligand to the receptor [154] or the existence of undiscovered endogenous 
ER modulator[155]. Further crystallography studies with different ligands have showed 
that the conformational and structural changes induced by various ligands help 
contribute to their agonist and antagonist effects[156]. The ligand-binding domain has a 
helix called helix12 with a key function; when the ligand is agonist like estrogen, the 
helix seals the binding pocket and recruits coactivators to the transcriptional complex 
on the surface of helix 12. On the other hand, in binding of an antagonist, like 
raloxifene, helix 12 cannot seal the binding pocket due to the bulky side-chain which 
causes helix 12 to rotate away from an “agonist” position [155, 156]. The 
phosphorylation of the ER at tyrosine 537 within the LBD region is implicated in DNA 
binding, dimerization and in the conformational changes of the ER [157, 158] and its 
ability to stimulate transcription [159]. The last domain in ER protein, the 
transactivation function (AF-2) needs an agonist ligand for its activity. There is a third 
activation domain, termed AF-2a [160, 161] which has either constitutive activity or a 
stimulatory effect on AF-1. Finally, there is a negatively acting domain which is also 
involved in binding of the heat-shock protein 90[162]. 
 16 
 
ERβ is very similar to ERα in its overall structure but to some extent shorter than ERα 
[142]. ERβ is reported to have 95% homology in the DBD and 53% homology in the 
LBD. The high degree of homology between the DBD of two ER receptors indicate 
that they can heterodimerize and bind to EREs. The formation of mixed ER dimmers 
has been shown both in vitro and vivo [142]. The AF-1 Activity of ERβ is absent or 
very small. This explains, the differences in transcriptional activation of specific 
estrogen responsive genes between the two subtypes[163] and the fact that tamoxifen 
(mixed antiestrogens) shows partial agonist/antagonist activity with ERα but exclusive 
antagonist activity with ERβ [164]. The homology of ERα and ERβ within LBD, along 
with their different tissue distribution suggests that the two receptors may exert 
selective and different responses with different physiological roles. Thus, the balance of 
ERα and ERβ co-expression in breast cancer might have an effect on progression 
[165]and their ligand selectivity may become important in the management of BC. A 
better understanding of the role of ERβ and its significance in BC is fundamental.  
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Figure 4; A schematic comparison of ERα and ERβ, with the degree of homology 
shown as a percentage is outlined in figure 4. Both ER proteins consists of six regions 
(A, B, C, D, E and F) and five domains (AF-1/AF-2 (transactivation domain), DBD; 
DNA binding domain, LBD; ligand binding domain. and hinge) 
 
Figure 4.Schematic comparison of ERα and ERβ. 
 
 
ERα  
                     AF-1             DBD     Hinge     LBD                               AF-2 
 
ERβ 
 
 
1.4.2 Estrogen receptors expression in normal breast and BC  
Epithelial growth and development of normal breast is complex and understanding the 
factors involving and steering - these event is important as the same factors play a role 
in the development and progression of malignant breast cancer[166]. The breast gland 
mainly develops during puberty and afterward throughout pregnancy and lactation. The 
ovarian function is essential for the development of the breast, it is known that the 
breast does not develop in the absence of functional ovaries and the premature loss of 
ovarian function reduces breast cancer risk. Thus, estrogen and progestrone (ovarian 
hormones) are necessary factors for both normal and abnormal processes in breast 
glands [167]. The cells that express ERα and PR are found within the luminal epithelial 
but not the myoepithelial or stromal cells of the human breast[168]. About 10-15% of 
the premenopausal breast epithelium expresses ERα [168, 169]. In contrast, ERβ is 
expressed in approximately 85% of both luminal and myoepithelial cells[170]. 
Furthermore, ERβ is expressed in stromal cells in both fibroblast and endothelial cells. 
The fact that luminal cells account for more than 90% of the epithelial proliferation that 
happens in response to cyclical altering of ovarian hormones secretion during the 
menstrual cycle, shows that they are the major target cells for these hormones. Several 
investigators have reported that cells in normal breast that proliferate in response to 
steroid hormones neither express ER nor PR but are usually located next to ERα and 
PR-positive cells [169, 171]. Dissimilar, ERβ is expressed in many proliferative 
epithelial cells [172, 173]. These findings have led to the suggestion that ERα-positive 
cells produce growth factors in response to estrogen and stimulate adjacent cells by a 
paracrine stimulation leading to their proliferation. The paracrine model was confirmed 
in steroid receptor knockout mice by Brisken at al [174, 175]. In hormone dependent 
breast cancer the expression of ERα and PR is increased while the expression of ERβ is 
decreased. This data fits in with experimental studies indicating that ERβ interacts with 
ERα and may inhibit estrogenic actions by the means of this interaction [176]. In 
addition, ERα-positive cells in breast cancer are known to be proliferative, suggesting 
either the response to estrogen is cell autonomous or that the response to growth factors 
is in an autocrine way (see schematic figure 1)[177, 178].  Mutation of the ERα gene 
may elevate its sensitivity to estrogen[179]. 
 
 
A 1 16%      B     C 95%   D 2        E 53%               F  F 
   C  95%  D29%   E    53%                           F 
A         B              C        D E  F 
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Figure 5; demonstrates the; growth in normal and carcinoma cells. In normal cells, 
estrogen stimulates ERα-positive cells to produce growth factors. These growth factors 
stimulate proliferation of ERα-negative cells by paracrine way. In cancer epithelium a 
shift from paracrine to autocrine or cell autonomous growth happens. It is possible that 
stromal cells so produce local growth factors. 
 
Figure 5.Growth in normal and carcinoma cells. 
Cancer:                                     Normal: 
Autocrine or                                   paracrine promotion of proliferation 
    Cell 
Autonomus 
 
 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
   
1.4.3 Methods for the measurement of ER in breast cancer 
The assessment of ER status has been a useful prognostic and predictive factor in BC. 
Following the identification of ER through the 1960s, Jensen suggested that the 
measurement of ER levels in breast cancers could help predict the response to 
endocrine treatment ([6]. Since then a range of assay methods have been used to 
determine ER content in breast cancer samples. Improvement and development of the 
new assay methods for assessing hormone receptors have led to simpler, less extensive 
and less time consuming measurement of ER in daily clinical use.  
 
1.4.3.1  Biochemical methods 
The biochemical ligand-binding assay (LBA) was the first method that became 
standard for ER detection and measurement. Dextran-coated charcoal radioactive LBA 
was most commonly used. This assay was carried out on cytosol from fresh tumor 
tissue. The tumor tissue had to be frozen immediately after surgery and removed from 
the patients and stored under special conditions. The main advantage of this method is 
that it gives an objective and reproducible quantitation of ER under conditions of good 
Epithelial cell Epithelial cell 
ERα 
+ 
 ERα 
- 
?   ?   ? 
? 
? 
?       
?+
+
+
+ 
Stromal 
cell 
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quality control [180]. However, the assay has some disadvantages; it needs a relatively 
large amount of fresh tissue, it measures ER content of the whole tissue consisting 
epithelia cells, stroma and saturation of the receptor sites by endogenous or exogenous 
ligand may lead to low or false-negative results. The assay involves the use of 
radioactive material and thus requires centralization for accurate performance.  
 
1.4.3.2 Immunohistochemistry 
The advance of monoclonal antibodies to the receptor makes the development of new 
assay methods possible, in order to overcome the difficulties associated with the LBA 
assays. Enzyme immunoassay (EIA) was developed for tumor cytosol which was 
somewhat more sensitive than biochemical methods. Finally, immunohistochemical 
assays (IHC) developed that measure ER only in cancer cells. The IHC assay has many 
advantages [181]; requires a small amount of tissue and can be performed on the 
material from fine needle biopsy and core biopsy, making it possible to examine 
receptor status during therapy in metastatic breast cancer. This assay does not require 
fresh tissue and works on routine fixed histological sections as well as archival 
material. The IHC assay can detect ER regardless of its functionality or occupancy. 
Another advantage is that the IHC assay only measures the ER content in cancer cells. 
Simplicity, low cost, and no need for specialized equipment, has meant IHC has been 
the method of choice for determination of ER in clinical daily work since 1990. It 
should be mentioned that IHC has several drawbacks. Result can vary substantially due 
to tissue fixation, procedural conditions, and type of antibody [182] or antigen retrieval 
method [183] used. The semiquantitative and subjective nature of IHC assessment with 
limited standardization, quality control, and commonly accepted cutoff point and 
scoring complicates the easy use of IHC analysis in determination of ER in the clinic. 
 
1.4.3.3 Cut-off point 
To put an appropriate cutoff point which separates ER-negative from ER-positive 
tumors is a major concern with any ER assay. It is even more important when cutoff 
point is used to predict response endocrine therapy. Early studies correlating assay 
results with clinical response to endocrine therapies indicated that tumors with even a 
small amount of detectable ER protein had a significantly higher response rate than 
those with undetectable ER levels[184]. For the DCC LBA, these levels were about 3 
fmol/mg protein, which were at the limit to the assay’s sensitivity (ref). However,  
arbitrary cutoff points as high as 20 fmol/mg cytosol protein have been used by some 
laboratories, perhaps because tumors with higher ER levels were known to be most 
likely to benefit from hormonal therapy[185]. It is most possible that some patients 
were misclassified as ER-negative and consequently went without endocrine therapy 
from which they had a good chance of benefiting. Moreover, such misclassification 
could have led to the faulty impression that hormone therapy has some effect in patients 
with ER-negative tumors. 
It is even more difficult to adapt an optimal cut-off point for IHC assays. Several 
studies have assessed the ability of ER by IHC to predict a response to hormonal 
therapy. However, many of these studies were small, and were performed with 
antibodies most suitable for fresh-frozen tumor samples [186], a procedure that is not 
very relevant at present, when practically all IHC determination of ER is performed on 
formalin-fixed and paraffin-embedded samples. In addition, the definition of ER-
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positive and negative varied because of lack of validation and standardization regarding 
both technical and scoring aspects of this assays. However, recent reports using a 
validated protype protocol and scoring system, in large studies, are suggesting a 
stringently low cut-off point. A score value>2, specimens with >1% of cells staining, 
was considered positive, and was the optimal cut-off point for predicting improved 
outcome [181, 186]. Moreover, the 11th St Gallen conference defined endocrine 
responsiveness as the presence of any detectable ER [187]. 
 
1.4.4 Microarray  
DNA contains all genetic information and gene expression is demonstrated by the 
transcription of the information limited within the DNA into messenger RNA (mRNA). 
Every somatic cell has a complete set of chromosomes and identical genes settings but 
depending on the type and function of the cell, most of these genes are inactivate with 
only a small portion of genes expressing to give the each cell its characteristic features. 
Moreover, a cell type responds to different stimuli by means of activating and 
deactivating a gene or a group of genes, resulting in expression of particular genes as 
necessary. Recently, investigators have used the microarray technology for analyzing 
gene expression profile in diseases by studying the steady level of mRNA. 
   
Despite the relatively short life of microarray techniques, increasing numbers of 
microarray have been performed and the results of these studies have already impacted 
our knowledge about various diseases, including cancers. Gene expression analysis by 
the means of microarray in breast cancer has disclosed signatures leading to molecular 
classification of BC, and has provided gene expression profiles with potential to predict 
prognosis or/and predict response to a given therapy. However, there are some 
difficulties associated with the microarray method that can challenge its potential. 
These pitfalls account for conflicting results and lack of reproducibility-shown in 
microarray studies. Variations in microarray analysis are caused by: 1) Array 
manufacturing processes, 2) Preparation of samples, 3) Hybridization of the sample to 
the assay and 4) Quantification of the spot intensities. 
 
1.4.4.1 Array production 
There are several platforms for performing microarray but the most used platforms is 
cDNA using probes constructed with PCR products of up to a few thousands base pairs 
and oligonuclotide arrays. In short, the microarray method consists of probe (molecules 
being immobilized), target (molecules in the sample; mRNA) and a detection device. 
There are three ways to fabricate a DNA microarray: (1) contact spotted, (2) non-
contact printing and (3) in situ synthesis. Probe is a “spot” of known DNA, or 
oligonuclotide printed on a support of glass, silicon or nylon in defined arrangement. 
There are some factors during fabricating DNA microarray that affects DNA 
performance; such as spotter type (pin, inkjet), robotics, humidity, temperature at 
spotting, probe concentration, spotting buffer, immobilization chemistry, blocking 
technique, hybridization conditions, probe sequence and target preparation[188]. To 
avoid or reduce variability associated with DNA microarray, it is possible to use 
commercially available DNA microarray with associated kits or devices. 
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1.4.4.2 Samples 
Using high quality RNA is recommended for performing microarray analysis. The 
biological samples can be provided by several means; surgical excision of tumors/ 
tissues, biopsies (core biopsy, fine needle aspiration), cell culture. Moreover,   
considerable quantities of human cancer tissues have been conserved as fresh frozen 
tissue or cells in biobank or are obtainable in formalin-fixed, paraffin-embedded 
archival materials. However, the tissue processing has not been optimal in most 
histopathological situations. Furthermore, it has been reported that mRNA degradation 
depends on type of tissue, type of cells and size of mRNA [189-191]. In addition, 
fixation of tissue in formaldehyde results in degradation of RNA[192] and paraffin-
embedding results in fragmentation of RNA[193]. For these reasons, the amount of 
RNA extracted from formalin-fixed, paraffin-embedded material is low and modified 
with poor quality.  On the other hand, for microarray proposes, fresh tissues/cells 
contain high quality mRNA. After surgical removal, samples should as soon as possible 
be immersed into liquid nitrogen and conserved at -80º to avoid mRNA degradation.  
An alternative, which has also been shown to prevent mRNA degradation, is putting 
samples in a RNase buffer before being snap frozen in liquid nitrogen [194, 195] . 
Another problem regarding tissue sample is the heterogeneity of samples with different 
amount of cells. Also, several factors, including the specimen type, preservation 
treatment of the tissue, extraction method, type and length of storage, and freeze and 
thaw affect the molecular quality of the tissue [196, 197]. To avoid variability related to 
sample handling it is important to have a standard protocol for sample processing that 
allows both traditional histopathological diagnostic assessment and molecular 
investigation. Interlaboratory variability can be avoided by performing microarray 
analysis in one central laboratory. The MINDACT trial (Microarray In Node-negative 
Disease may Avoid ChemoTherapy; EORTC) which is a prospective study evaluate the 
Mammaprint as a risk assessment tool, has adopted standard operating procedures for 
collection of samples with all microarray being performed in one laboratory in the 
Netherlands [198]. 
 
1.4.4.3 Hybridization 
Many instants during hybridization can cause variation in gene expression analysis. The 
preparation of cDNA, changes in temperature, the agent qualities and labeling are some 
examples. Following standard protocol, using standard high quality agents and 
performing the microarray in a central laboratory can reduce variation. 
 
1.4.4.4 Quantification of intensities 
Depending on the choice of radioactive label or dye, single or dabble dye, the sort of 
detective device and the microarray platform some false variation in probe intensities 
can occur which result in false level of gene expression. After subtraction of 
background noises, variations in intensity from probe to probe or chips to chips for 
samples need to be normalized to obtain a trustworthy level of gene expression. The 
normalization process has been performed in different way. One commonly used 
method is normalization to a proper internal control. The internal control could be a 
gene or group of genes with no or minimal variation in their gene expression. 
Traditionally, the expression of “housekeeping” genes such as; actinβ, GAPDH 
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(glyceraldehydes-3-phosphate dehydrogenase) and 18s ribosomal RNA is used to 
normalize gene expression. However, several studies have indicated that the gene 
expression of “housekeeping” gene may considerably vary between different tissues 
types, disease states and experimental conditions[199] and have therefore excluded 
these genes as internal control genes. Another approach is to normalize the expression 
of each gene to total RNA or the mean expression of all genes included in the 
experiment (global normalization). Some authors suggested specific internal control 
(gene/s) for different tissue and pathological condition. We normalized the gene 
expression level to mg of tissue corresponding approximately to the number of cells.  
         
1.5 TREATMENT OF BREAST CANCER 
The treatment of breast cancer in Sweden is based on evidence–based medicine and 
follows the international and national guidelines. In the Stockholm area, a local therapy 
synopsis corresponds the recent recommendations on treatment of BC and directs the 
decision making to suggest adequate treatment to patients. This protocol has been 
revising regularly to adjust for new recommendations. The other characteristic of breast 
cancer treatment in Sweden is a multidisciplinary approach in management of BC as 
well the other cancers. The team includes the oncologist, surgeon, pathologist and 
radiologist and other disciplines such as the psycho-social team, dieticians and 
physiotherapists who discuss each case before and after surgery. Multidisciplinary 
management of BC and guidelines contribute to an improvement in BC overall survival 
rates [200]. In Stockholm and Gotland County the majority (98%) of patients with 
breast cancer diagnosis have been discussed in a multidisciplinary team before 
surgery[200]. 
 
1.5.1 Surgery 
Surgery is the first therapeutic action for majority of primary BC with removal of the 
macroscopically tumor. The surgical techniques include breast-conserving surgery, 
mastectomy and axillary lymph node sampling or dissection. For most patients with 
stage 1 and 2 breast cancer and for some patient with T3 N0-1 when the ratio of tumor/ 
breast is allowed or after down-staging by neoadjuvant therapy, breast-conserving 
surgery in combination with radiation against remaining breast tissue is as safe as 
mastectomy[201, 202].  In Sweden about 93% of patients with primary BC underwent 
surgery in 2008, of which about 55 % were operated by means of breast- conserving 
surgery[200] and the remaining with mastectomy. The removal should be radical, i.e. 
on microscopic examination; also the excised tumor should be surrounded by a margin 
of normal tissue. 
Information on the lymph node involvement is the most important data and has great 
impact on decision on postoperative adjuvant therapy. During last 20 years, the use of 
“sentinel lymph node biopsy” which indicates if the first lymph node/s into which a 
tumor initially drain, has reduced the more extensive technique of axillary surgery. 
Also, if the sentinel node is free from cancer cells, there is no need for axillary 
dissection. However, if the sentinel node is involved, an axillary dissection has to be 
performed. Axillary surgery (- dissection) is associated with the risk of morbidity in the 
arm, especially the risk of lymph edema[203] and now is less frequent. In Sweden 
about 71% of all patients that were operated for primary BC, underwent sentinel node 
biopsy and about 75% of them had negative lymph node results[200]. 
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1.5.2 Radiotherapy 
Radiotherapy is a sort of local treatment that has been given to patients with BC both as 
adjuvant and palliative.  Breast-conserving surgery in patients with invasive breast 
cancer should be followed by radiotherapy to reduce loco-regional recurrences [204, 
205]. Clarke et al reported [206]that radiotherapy after surgery reduced the risk of loco-
regional recurrence by two-thirds compared with surgery alone and improved 15-year 
breast cancer survival by 5.4% in the radiotherapy group including both breast –
conserving surgery and mastectomy. In the case of mastectomy, radiation to chest wall 
is indicated with poor tumor marginal, with multiple tumors in breast, and with large 
tumor size. With more than three lymph nodes involvement, loco-regional radiation 
should be given.  
 
1.5.3 Chemotherapy 
The purpose of chemotherapy like other systemic therapy is to destroy potential 
micrometastases when given postoperative (adjuvant) and reduces the risk of 
recurrences, leading to prolongation of disease free survival and overall survival. 
Chemotherapy as well has been used in metastatic breast cancer with good results. 
Recently about 5 to 10 % of patients with typical locally advanced BC have been given 
systemic therapy with mostly cytotoxic agents before operation (Neo-adjuvant). The 
main aim for the neo-adjuvant approach is to reduce tumor size, to evaluate the effect 
of given treatment and to avoid mastectomy.  There is no apparent survival advantage 
to neo-adjuvant chemotherapy compared with adjuvant chemotherapy [207]. Benefit of 
adjuvant cytotoxic has been shown for several decades [208-210]. In an overview of 
randomized clinical trials, anthracycline-based polychemotherapy reduced the annual 
breast cancer mortality by 38% in patients younger than 50 at time of diagnosis and 
20% for patients which were 50-69 years old[211]. Furthermore, chemotherapy with 
docetaxel and paclitaxel agents in comparison with anthracycline has further improved 
the outcome for patients with invasive BC [212-214]. 
  
1.5.4 Endocrine therapy 
Endocrine therapy of breast cancer started over 100 years ago, also, long before any 
knowledge on estrogen, by ovarian ablation of patients with metastatic breast cancer[4] 
Endocrine therapy of BC with tamoxifen started four decades ago. Since then large 
bodies of evidence indicate the usefulness of tamoxifen both as adjuvant and in 
metastatic breast cancer. Early Breast Cancer trialist has with interval overviewed all 
randomized trial of tamoxifen, with analysis of about 8000 women with ER-negative 
BC showing no effect of tamoxifen in ER-negative patients. By contrast, the effect of 
tamoxifen in 18000 ER-positive and 12000 women with unknown status were obvious 
after 10 years of follow-up: one year of tamoxifen reduced recurrences  with 21%, 2 
years with 29% and 5 years with 47%, whereas proportional reduction in mortality was 
12,17% and 26% respectively[215]. A recent review of randomized studies reported 
31% reduction of the annual death rate in ER-positive tumors, as a consequence of 
tamoxifen treatment for 5 years[211]. In contrast, tamoxifen has no benefit in ER-
negative breast cancers [216]. Aromatase inhibitors inhibit conversion of androgens to 
estrogens. Aromatase inhibitors in comparison to tamoxifen have only marginal effect 
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on survival [217, 218]. The same result seems to be the case in sequential treatment, 
tamoxifen for 2-3 years, followed by aromatase inhibitor [219, 220]. However, the new 
recommendation is first AI followed by tamoxifen because most recurrence happened 
during first 1-3 years. In premenopausal women ovarian ablation which can be 
achieved by surgery, radiotherapy and more commonly by gonadotropin-releasing 
hormone (GNRH) agonist, which is associated with reduction in breast cancer 
recurrence and mortality [211]. 
 
1.5.5 Biological therapy 
Biological treatment means treatment with substances that are made in the body or that 
can block the growth of cancer cells. The first biological treatment for breast cancer 
that became available in the late 1990s was trastuzumab, which is an antibody against 
HER2/neu receptor. Initially, was approved in metastatic breast cancer. HER2/neu is 
amplified in about 15-20% of breast cancer tumors. The mechanism of action is 
through suppression of HER2 stimulated growth and potential also activation of the 
immune system to more effectively eliminates the cancer cells. There are several 
reports that one year of adjuvant trastuzumab in patients with amplified HER2/neu 
breast cancer tumor reduced risk of recurrence with 50% [221, 222]. A similar result 
was shown by FinHer trial despite only 9 weeks of adjuvant trastuzumab. However, a 
recent update of the FinHer trial still showed the benefit of 9 weeks trastuzumab but 
called for further research about the duration of adjuvant trastuzumab therapy [223]. 
Bevacizumab (Avastin) is another biological molecule; a humanized monoclonal 
antibody against vascular endothelial growth factor (VEGF), a pro-angiogenesis factor 
has shown to be effective in metastatic BC in terms of an improvement in progression 
free survival. It is indicated for the first line treatment of patients with MBC who have 
HER2-neu negative tumor in combination with paclitaxel. Several others biological 
agents, such as lapatinib (Tyverb), Sunitinib (Sutent) have already been used in 
metastatic patients and others are currently in different phases of clinical investigation. 
Ongoing studies will evaluate the effectiveness of these agents in adjuvant settings.  
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2 AIMS  
 
 
 ♦ To investigate if the gene expression differences between ER-positive and ER-
negative breast carcinoma in vitro is only correlated to phenotypic trait defined by ER 
status or endocrine sensitivity or if there is further diversity (paper I). 
 
♦ To investigate in clinical material, if the potential of breast cancer for progression and 
metastasis is only related to endocrine sensitivity and ER status (paper IV). 
 
♦ To investigate if the current use of IHC for determination of ER status is as proper as 
cytosol assays and has at least the same ability to predict response to endocrine 
treatment as biochemical methods (paper V). 
 
♦ To investigate how breast cancer heterogeneity as well as  sample collection, storage, 
processing, and normalization of RNA, influence the result of gene expression arrays 
and the gene expression array’s  potential to be applied in clinical management of 
breast cancer (paper II and III). 
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3 PATIENTS, MATERIALS & METHODS 
3.1 PATIENTS  
3.1.1 Patients (paper IV and V) 
This thesis is partly based on the material of about 2600 patients who underwent 
surgery for primary breast cancer during the period November 1976 and to December 
1996. These patients were included in one of three well-defined, controlled clinical 
studies of adjuvant endocrine therapy conducted by the Stockholm Breast Cancer Study 
Group, the Stockholm Adjuvant Tamoxifen Trial 3 (STO-3), the Stockholm part of the 
Zoladex in premenopausal patients (ZIPP-trial, STO-5), and a continuation of the STO-
3 trial which only included patients  whose tumors were classified as ER-negative ( 
STO-7) (Figure 6). 
 
STO 3:  
From November 1976 through June 1990, a total of 2,738 patients, irrespective of 
hormone receptor content, entered the trial. Before randomization the patients were 
stratified according to stage of disease and primary therapy. There were 1,780 patients 
with a pathological tumor diameter of 30 mm or less and no lymph node metastases 
(low risk) and 958 patients with “high risk” tumor with either lymph node metastases or 
tumor size exceeding 30 mm on pathological examination or both. In the “low-risk” 
group 432 patients were treated with breast conserving surgery including axillary 
dissection plus radiation to the breast (50 GY/5 weeks), the remaining 1,348 patients 
had a modified radical mastectomy.  The “low-risk “patients were randomized between 
adjuvant tamoxifen and no adjuvant systemic therapy.  
 
Zipp-trial (STO-5):   
This trial included premenopausal patients (< 6 months since last menstruation) with 
invasive breast cancer treated with a modified radical mastectomy or breast conserving 
surgery and an axillary dissection or biopsy. The patients with breast conserving 
surgery also received adjuvant radiotherapy to the breast (50Gy/5weeks). The patients 
were included in study irrespective of ER status. All patients with node positive disease 
electively received adjuvant cytotoxic chemotherapy and those with four or more LN 
metastases as well received radiotherapy. 
 
STO-7: 
This study was a continuation of the STO-3 trials and was designed to evaluate the 
effect of adjuvant endocrine treatment in operable, ER-negative postmenopausal 
women aged below 75years. The main inclusion criteria were: invasive breast cancer, 
postmenopausal (> 6 months since last menstruation), operable tumor, ER-negative 
(ER< 0.05 fmol/µg DNA) and no metastases. Patients who were operated with breast 
conserving surgery received 50Gy/5weeks radiation to the breast. The node-positive 
patients electively received post operative locoregional radiotherapy (46Gy/4.5 weeks). 
Randomization was between tamoxifen 40 mg daily for 2 years versus no adjuvant 
systemic therapy. 
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Figure 6.Flow chart for the trials IV and V.STO=Stockholm; pN= pathologic lymph-
node; pT= pathologic tumor size; Tam= tamoxifen; CYT=cytotoxic; number of cases in 
brackets. 
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For the purposes of paper IV, we selected 2,562 patients from all aforementioned three 
trials with known ER status randomized to tamoxifen or control. These patients  did not 
receive chemotherapy. The patient characteristics by trial are shown in table 4. 
 
For the purpose of paper V, we chose the 1,780 “low risk” patients from the STO-3 trial 
because they received no adjuvant chemotherapy known to affect outcomes. These 
patients were randomized between no systemic therapies versus tamoxifen in contrast 
to the”high risk” group who also was given chemotherapy. 
 
Table 4.Patient characteristics by trial. 
 
Characteristic  STO3 STO5 STO7 Total 
     
Period of recruitment 1976-1990 1990-1996 1990-1996 1976-1996 
     
Age, median (range) 62 (45-77) 46 (30-55) 62 (44-75) 61 (30-77) 
     
Allocated treatment: 
 
Tamoxifen 
Control 
 
 
1,007 (50) 
1,005 (50) 
 
 
 
101 (50) 
101 (50) 
 
 
173 (50) 
175 (50) 
 
 
1,281 (50) 
1,281 (50) 
Histopathological 
tumor size:  
 
<20 mm 
>20 mm 
Missing data 
 
 
 
 
1,176 (58) 
      803 (40) 
33 (2) 
 
 
 
113 (56) 
89 (44) 
- 
 
 
 
170 (49) 
175 (50) 
3 (1) 
 
 
 
1,459 (57) 
1,067 (42) 
36 (1) 
Histopathological 
nodal status: 
 
N0 
N1-3 
N4+ 
Missing data 
 
 
 
 
1,536 (76) 
313 (16) 
155 (8) 
3 (0) 
 
 
 
202 (100) 
- 
- 
- 
 
 
 
233 (67) 
82 (24) 
33 (9) 
- 
 
 
 
1,971 (77) 
395 (16) 
188 (7) 
3 (0) 
ER status: 
 
Negative 
Positive 
 
 
   404 (20) 
1,608 (80) 
 
 
 44 (22) 
158 (78) 
 
 
341 (98) 
 7     (2) 
 
 
  789 (31) 
1,773 (69) 
     
Median follow-up(y)    15.5 6.4 6.7 13.8 
Total number of 
patients 
 2,012 202 348 2,562 
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3.1.2 Patients (paper III)  
Human breast cancer tissues and normal breast tissues from women who were referred 
to Karolinska University Hospital, Stockholm were collected. Routine breast surgery 
procedures were used, and to avoid RNA degradation, the tissue samples were put into 
RNAse free tubes containing RNA later buffer (Qiagen GmbH, Germany) within 10-15 
min after operation. The samples consisted of invasive ductal breast cancer, ductal 
cancer in situ as well as normal breast tissue. Laser capture microscope (Arcturus Ltd, 
UK) was used to collect normal (non-malignant) and malignant cells from the tissue 
section (one patient). The cells were picked by a skilled pathologist and were collected 
into RNAse-free tubes and immediately prepared for RNA extraction and amplification 
according the manufacturer’s protocol (Arcturus Ltd). 
 
3.1.3 Material (paper II)  
Canine breast cancer and lymphoma tumors were taken from dogs referred for routine 
surgery at the University Small Animal Hospital, Uppsala. Samples consisted of four 
tubulopapillary carcinoma, two complex carcinoma, two benign mixed tumors, one 
solid carcinoma, and one fibroadenoma. The lymphoma was a high-grade, large-cell B-
cell lymphoma. Routine surgery and procedures were used. 
 
3.1.4 Cells (paper I) 
In paper I, human breast cancer cell lines were used, ER-positive cells (MCF-7, ATCC 
no. HTB-22), ER-negative cells (MDA-MB-231, ATCC No. HTB-23), normal breast 
cells (H2F), and lymphoblastoid cells (CEM). MCF-7 and H2F were grown in 
minimum essential medium. H2F were supplemented with sodium pyruvate. MDA-
MB-231was cultured in Dulbecco’s modified Eagle medium. CEM was kept in RPMI. 
 
3.2 FOLLOW-UP STRATEGIES IN PAPER IV AND V 
Clinical visits took place every 3 months during the first 2 years, every 6 months during 
the next 2-5 years and yearly thereafter. These visits routinely included a physical 
examination and an annual mammogram. With a possible relapse blood sample, chest 
x-ray, bone scans, etc were performed.  Disease relapse was confirmed when possible 
by biopsy. However, visceral and bone metastases were sometimes established on 
obvious radiological evidence. Recurrence was dated from the first evidence of relapse. 
Death preceded by breast cancer relapse was classified as breast cancer deaths and 
otherwise considered to be intercurrent death. The proportion of patients lost to follow-
up was <1%. In paper IV results were based on follow-up until December 31, 1999 and 
in paper V until December 30, 2005. 
 
3.3 DETERMINATION OF ER 
3.3.1 Cytosol (paper IV and V) 
The ER cytosol assays were performed in one laboratory in Stockholm, a participant in 
the Swedish national quality control program for hormone receptor laboratories. Tumor 
samples were collected and processed according to study protocols. ER was determined 
by isoelectric focusing before 1988 when an enzyme immunoassay was used. The 
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receptor values were normalized to DNA and tumor with a receptor content of≥ 0.05 
fmol/µg DNA considered to be ER-positive. 
 
3.3.2 Immunohistochemistry (paper V) 
The IHC was performed using the Ventana automatic BenchMark machine (Ventana 
Medical Systems). A rabbit monoclonal ER antibody (Spl 250) was used and all 
procedures were performed following Ventana instructions. 
 
3.4 CDNA MICROARRAY 
3.4.1 RNA extraction  
Total RNA was isolated from cultured cells (paper I) using RNA Quick Kit as 
described by Qiagen Kit (RNeasy Mini Handbook, 1997). 1x10
7
 cells in 600µl RNeasy 
lysis buffer were homogenized to which 600 µl of 70% ethanol was added. After 
mixing, 700µl of solution including any precipitate was placed in an RNeasy mini spin 
with a membrane in the bottom and centrifuged for 15s at 8,000g. The first washing 
was performed by adding RW1 buffer and centrifuging for 15s and the second washing 
by adding a RPE buffer. To dry the RNeasy membrane, RPE buffer was added and 
centrifuged for 2 min at 14,000g. Finally, the mini spin column with membrane was 
transferred into a new collection tube and 30µl of RNase-free water was added and 
centrifuged for 1 min to elute. The total RNA was measured at 260 and 280 nm in a UV 
spectrophotometer.  
Total RNA from canine tissue (paper II) and human breast cancer (paper III) was 
isolated using an RNA-Bee isolation Kit (BioSite, Sweden). Samples of 50 mg tissue 
were homogenized in 1 ml RNA-Bee, and chloroform was added, after putting on ice 
for 5 min and centrifuging for 15 min at 12,000 g. The colorless aqueous phase was 
collected and 0.5 ml of isopropanol was added and after 10 min in room temperature, it 
was centrifuged for 5 min at 12,000 [224]g and the RNA pellet was washed twice. The 
total amount of RNA was measured at 260 and 280 nm in an UV spectrophotometer. 
The integrity of the total RNA was analyzed on a denatured 1% agarose/formaldehyde 
gel according to the manufacture’s standard protocol (Qiagen GmbH). 
 
3.4.2 cDNA array in paper II and III 
Total RNA (5µg) from samples was used for each array. Biotin probe preparation and 
hybridization were conducted according to the manual provided by Super Array (Super 
Array Ltd.). The only modification to the protocol was changing the washing 
temperature and time from 60º C for 15 min to 68º C for 20 min for washing solution 
no. 1 and 2. Quantitative data was obtained using AGFA Curix 60 photographic film 
(AGFA, Sweden).   
For samples from cell culture (paper 1), the total RNA (5µg) was used as a template for 
biotinylated probe synthesis using the protocol of Nonrad-GEArray as described by 
SuperArray (Nonrad-GEArray, 2001). The relative gene expression was detected by 
chemiluminescence signals using the alkaline phosphatase substrate. The amount of 
cDNA on the film was scanned and measured by ImagerMaster Total Lab v1.11 
(Amersham Pharmacia Biotech, Sweden). 
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3.4.3 Gene setting 
A panel of 18 genes, corresponding apoptosis, DNA repair, cell cycle, DNA damage 
signal pathway and growth factors and receptors, was used in study I.  
Human Cancer Pathway Gene Array with 87 genes (GEArray Q Series, HS-006; 
SuperArray Ltd.) was used for study II. 
Human Signal Transduction Pathway Finder Gene of 87 genes, corresponding to 18 
signal transduction pathway (Super Array Inc; Maryland, Bethesda, MD, USA) was 
used for studies II and III. 
 
3.5 STATISTICAL METHODS 
Time to relapse was calculated from the date of randomization to first event and in the 
absent of an event, to the last day of follow-up. Survival time was calculated from the 
date of randomization to the date of death or follow-up. Crude cumulative incidence of 
disease recurrence was estimated using the Kaplan-Meier technique. Proportional 
hazards regression models were used to relate treatment and ER status to time to 
recurrence and time to death after controlling for age, tumor size and nodal status. 
Results are presented as crude cumulative incidence rates at 10 years and hazard rate 
ratios with 95% confidence intervals. Reported p-values refer to Wald tests. The 
median follow-up time was estimated with the reverse Kaplan-Meier method. The 
software used for the statistical analysis was Stata/SE 10.0. 
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4 RESULTS AND DISCUSSION 
 
4.1 GENOTYPE OF ER-POSITIVE AND ER-NEGATIVE BREAST CANCER 
IN VITRO 
The estrogen receptor content in invasive breast cancer separates these tumors into ER-
positive and an ER-negative subtypes. The differences between these subtypes have 
been investigated in numerous studies both in vitro and in vivo. The endocrine 
treatment of BC has increased relapse free and overall survival of patients with ER-
positive BC. Tamoxifen is the most used endocrine therapy. It has been known that 
about 30% of ER-positive tumors do not respond to tamoxifen (de novo resistance) and 
among those who initially respond to tamoxifen the majority develop resistance 
(acquired). The mechanism(s) of endocrine resistance in BC patients has been studied 
extensively over the last two decades. 
In an in vitro study (cell culture, paper I), we ask how cells with ER-positive and ER-
negative genotypes differ in controlling events linked to growth factors, such as cell 
cycle control and apoptosis. We also included DNA damage signal pathway and DNA 
repair, because these events are important for responding to antitumor treatment. Using 
cDNA microarray, we studied gene expression of 18 genes related to above named 
events and pathways. The results revealed differences in gene expression of 10 genes of 
18 investigated between ER-positive CMF-7 cells and ER-negative MDA-231 cells. 
Genes related to cell cycle regulation, cyclin B1, cyclin E, cyclin D1, and cdc2p34 were 
overexpressed in both cancer cells compared to normal breast cells, however, the 
expressions were higher in the ER-negative cells (MDA-231) when compared to the 
ER-positive cells (MCF-7). The proliferation of cells is controlled at specific 
checkpoints in the cell cycle. Cyclin D1is involved in the control of events in the GI. 
Cyclin E is involved in late G1/S phase and cyclin B1has a key role in the G2 to M 
phase transition. Higher expression of cyclin D1 was found in tamoxifen-resistant 
MCF-7 these cells also; somehow bypass the inactivated ER, promoting cell growth. 
The ER-negative MDA-231 cells also grow without functional ER and the event/s 
behind the resistance may cause an elevation in the level of cyclin D1 and improved 
proliferation. The expressions of growth factors TGF-α and TGFβ2 and growth factor 
receptors EGFR, IGFR-1, IGFR-2 and TGFβR2 were elevated in both cancer cell lines 
with higher expressing of growth factors TGF-α and TGFβ2 in ER-negative cells .It is 
reported that ER activation stimulates synthesis of growth factors and receptors. In 
normal breast cells, these growth factors act in a paracrine way but in cancer cells they 
act in an autocrine way. Thus, despite a lack of ER, growth factors TGF-α and TGF-β2 
are synthesized indicating that these genes can be regulated even by a pathway other 
than ER. Whether or not this is the mechanism of endocrine resistance in breast cancer 
patients lacking ER is still open to debate. Insulin-like growth factor binding protein-3 
(IGFBP-3) was higher in ER-negative cells.  However, the expression of some growth 
factors and growth factor receptors were elevated, which indicates that these factors are 
related to growth stimulation in BC cells and possibly to the bypasses of the ER 
pathway in the ER-negative tumors.  Furthermore, the higher expression of the cell 
cycle components in the ER-negative cells may support the observation of the higher 
expression of growth factors. Genes related to DNA repair were tested by expression of 
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BRCA1 and BRCA2. BRCA1 showed the highest expression in MDA-231 cells and 
BRCA2 was expressed in MDA-231 but was undetectable in MCF-7 and normal breast 
cells (H2F). BRCA1 and BRCA2 are involved in the repair of DNA double strand 
breaks; in addition, BRCA1 seems to be involved in events regulating cell cycle 
checkpoints in a P53-independent way [225]. If this finding indicates that a higher 
DNA repair capacity is present in ER-negative primary breast tumors, these will have a 
growth advantage over ER-positive tumors when receiving antitumor therapy leading 
to DNA damages. The genes related to DNA damage signal pathways and apoptosis 
showed no differences in expression between ER-positive and ER-negative cell lines. 
Different gene expression between ER-positive and negative breast tumors was 
reported by other researchers [224]. Whether these profound gene differences between 
ER-positive and ER-negative tumors are only associated to endocrine responsiveness or 
indicate two distinct traits requires further investigation.  
  
4.2 CLINICAL OUTCOMES AND ER STATUS 
Studies on the pattern of gene expression in ER-positive and ER-negative breast cancer 
tumors have revealed profound differences according to ER status. However, it remains 
unclear if these differences reflect phenotypic traits in addition to sensitivity to 
endocrine therapy. We investigated the long-term pattern of disease recurrence among 
about 2,600 pre- and postmenopausal women with primary breast cancer according to 
ER-status. These patients were initially enrolled in three adjuvant trials and received 
tamoxifen or no systemic adjuvant treatment. A total of 2,048 patients were reported 
with locoregional, distant metastases and death. 1,041 patients died during the follow-
up of whom 543 were classified as breast cancer deaths. The hazard rate for any event 
was significantly lower among those who had been allocated tamoxifen and the benefit 
of tamoxifen was more pronounced when the analysis was restricted to the 1,773 
patients with ER positive disease.  There was no significant heterogeneity between the 
hazard rate ratios for the different distant metastatic sites. There was no evidence that 
tamoxifen was more effective in reducing, for instance, bony metastases than visceral 
metastases. Among the patients allocated to tamoxifen, patients with ER-positive 
tumors exhibited significantly lower hazard rates than ER-negative patients. In contrast, 
among those not allocated tamoxifen, there was no significant difference, according to 
ER status, of neither locoregional nor distant metastases. The results indicating the 
effect of tamoxifen only in ER-positive breast cancer tumors have been reported by 
several others groups and also are supported by Oxford overview. This study has 
several advantages, such as its large size, the long-term and almost complete follow-up, 
known ER status for all patients with all ER-measurement performed in the same 
laboratory with well validated methods. Furthermore, the design of the original studies 
permitted an unbiased analysis of the effect of tamoxifen in relation to receptor status. 
The results showed that ER-status have little or no prognostic value, that ER-status has 
strong predictive value for responding to  tamoxifen and that there is no significant 
differences between ER-positive and ER-negative tumors in terms of metastases 
pattern. There are conflicting reports about prognostic value of ER-status in early stage 
BC. Many early studies reported a more favorable prognosis for ER-positive patients 
[87-90, 226]. However, later studies indicated that the early advantages disappeared at 
longer follow-up [91-93]. The conflicting results are probably due to small studies, 
short follow-up, mixed study population, different cut-off point and lack of control of 
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other relevant prognostic factors, including use of tamoxifen. The gene expression 
differences between ER-positive and ER-negative tumors that have been shown in 
some studies [224] seem mainly to be related to endocrine sensitivity and not to 
metastatic potential. However, the minor benefit during the first five years for the ER-
positive versus ER-negative tumors in terms of cumulative incidence of events suggests 
that ER negativity in some cases may also be correlated with an increased tumor 
growth rate. 
 
4.3 PREDICTION ABLITY OF ER STATUS DETERMINED BY TWO 
ASSAYS 
Estrogen receptor content is a potent predictor of response to endocrine therapy in both 
primary and metastatic breast cancer. Consequently, the adequate method for 
determination of ER content is important in daily clinical practice as a false result can 
lead either withholding patients an effective treatment or receiving a useless treatment 
with many potential side effects. Also, two factors influence ER determination: firstly, 
the sensitivity and specificity of the methods and secondly, the establishment of an 
appropriate cut-off point. ER measurement was performed by cytosol assays up to 
approximately 1990 when it was replaced by immunohistochemical assays. However, 
the predictive ability of ER status regarding response to endocrine treatment was based 
on ER determination by cytosol assays. Furthermore, a high concordance between the 
two assays has been reported in several studies [227-230]. Several studies have as well 
shown the similar predictive and prognostic information with both assays [231-233]. 
The majority of these studies had a short follow-up, and many patients received a range 
of therapies, and only few studies compared these methods in an adjuvant randomized 
setting. In one study (paper V) we compared the ER determination by cytosol assays 
and IHC using material from a randomized trial conducted by the Stockholm Breast 
Cancer Study Group. The postmenopausal women with primary invasive breast cancer 
who received tamoxifen versus no adjuvant systemic therapy, whose tumor samples 
were left in the biobank, were included in the study. A total of 683 patients had tumors 
with known ER status by both methods (Table 5). 39 had ER-positive tumors by 
cytosol assays but negative by IHC; whereas the opposite pattern was found in 42 
cases. ER status by cytosol assays indicated that 147 of 683tumors were ER-negative 
and 42 of these tumors were ER-positive by IHC. The concordance between the two 
assays was high (88%). Patients with ER-negative tumors had no benefit from 
treatment with tamoxifen regardless by which assay the ER status was determined. 
Patients with ER-positive BC allocated to tamoxifen showed statistically significant 
better RFS but a reduction of OS by tamoxifen that was not statistically significant. We 
divided the patients in three groups by each assay: ER-negative, ER-positive and ER-
strongly positive. The results showed that the benefit of tamoxifen was unrelated to the 
percentage of stained cells, but in the group with ER-positivity measured by cytosol the 
benefit from tamoxifen appeared to be related to the concentration of ER and an 
increased benefit with ER≥1.0fmol/µg DNA. We found that RFS and OS were reduced 
mainly during the first 5 years, among the tamoxifen treated patients. Our data confirms 
that ER-status measured by IHC is similar to that determined by the cytosol assays. 
There is no consensus regarding the ER cut-off level. In the STO-3 study a cut-off level 
of 0.05 fmol/µg DNA was used because an analysis of treatment benefit versus ER 
levels did not show any benefit for ER below this cut-off level[234]. For the IHC we 
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used 10% stained cells as cutoff, however the 11
th
 St Gallen conference, defined 
endocrine responsiveness as the presence of any detectable ER. Our study could neither   
support nor reject this statement as the number of tumors stained between zero and 
25% were small. It seems the issue of cut-off level needs more investigation. 
 
Table 5.Determination ER by cytosol and IHC. 
      
 
 
 
 
 
 
 
4.4 THE USE OF CDNA MICROARRAY: POTENTIAL AND LIMITATION 
Gene expression profile by cDNA microarray and other techniques have been 
extensively used in cancer research, including for breast cancer. However, a number of 
factors and conditions during microarray can affect the final results of gene expression, 
with the following being some examples: the way tumor tissues are collected and 
preserved (which influence the mRNA integrity), the isolation technique, the choice of 
reference gene(s) or normalization, and tumor heterogeneity. In two method 
development studies, we check some of these parameters.  
The first study (paper 2) investigates alteration in RNA integrity by the means of RNA 
gel electrophoresis at different post-operative time- intervals on canine mammary 
tumors and malign lymphoma. We also performed gene expression profile of 87 genes 
representing human cancer pathway and 87 genes representing human signal 
transduction pathway using abovementioned tissues. The preparation of tissues was 
performed according to routine procedures, routine surgery, and handling of samples in 
the theatre. Thereafter, equal pieces were cut and put in tubes prior to fixation in liquid 
nitrogen at different time intervals after operation. After extraction of RNA, the quality 
of RNA was examined by mean of gel electrophoresis. The gel electrophoresis result 
showed that in lymphoma that has a homogeneous context, all RNA was degraded after 
30 min but in mammary cancer tissue degradation started between 15 and 30 minute 
and aggravated up to 4 hours. Furthermore, the result from cDNA showed that in 
mammary tissue some mRNA was not degraded, some was partially and some was 
completely degraded. By contrast, in lymphoma mRNA was not degraded at 15 min 
but all mRNA was completely degraded after 30 min. These results indicate the 
importance of tissue handling after surgery to fixation, heterogeneous expression of 
genes in the same tissue and heterogeneity of tumor tissue.  
In the second study (paper3) we analyzed the cDNA microarray results in normal and 
cancerous human breast tissue concerning standardization of gene expression, gene 
expression in various part of the tumour, and gene expression in cancer cells compared 
with cancer tissue. Normalization of gene expression can be done in different ways, 
such as to total RNA (most common) or mg tissue to DNA or number of cells. It is not 
easy to count the number of cells but mg tissue corresponds approximately to the 
number of cells in the tissue. Different results were shown from normalization to total 
RNA and then to mg tissue malign and normal tissue from the same patient. The 
 ER (IHC) Total 
ER (Cytosol) ER < 10% ER≥ 10%  
  ER < 0.05 105 42 147 
  ER ≥ 0.05 39 497 536 
Total 144 539 683 
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concentration of total RNA was 12 times higher in malign tissue compared with normal 
tissue but the gene expression was 9 times higher in malign tissue when normalizing to 
total RNA and 40 times higher when normalizing to mg tissue. A higher gene 
expression in malign tissue compared with normal tissue is expected because of higher 
proliferation rate in tumor cells. Gene expression in different parts of the tumor differed 
between 2-4 times. Furthermore, the expression of housekeeping genes that commonly 
are used as reference genes deviated markedly. A comparison between gene expression 
of individual cancer cells which were collected using microdissection by Laser Capture 
Microscope and gene expression of whole cancer tissue revealed an extensive 
difference in gene expression of detected genes.  
Gene expression analysis by cDNA microarray has the potential of addressing many 
issues concerning diseases; including breast cancer, and provides investigators a 
powerful tool. However, three set of drawbacks should be taken into account when 
interpreting microarray results: 1) the problems related to procedures such as time to 
fixation, fixation, preservation, isolation and extraction of RNA, probe making and 
hybridization 2) heterogeneity of gene expression in normal tissue, cancer tissue, 
between different tumor types and in the same tumor at different stages of 
development; and 3) the interpretation of data and the validation process. These 
differences explain at least partially the variations between findings for the same tumor 
type, which can often be more striking than similar. The results of our studies explain 
some of these contradictions and that some of these problems could be resolved by 
implementation of well accepted standard protocols. For these reasons the result from 
cDNA microarray should be interpreted with caution.   
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5 GENERAL CONCLUSIONS 
 
5.1 PAPER I 
•    Certain differences can be demonstrated in gene expression between ER- positive,    
endocrine sensitive and ER-negative BC cells in vitro. 
•    The expressions of some growth factors, growth factors receptors and cell cycle 
regulators and genes related to DNA repair pathway were different in ER negative and 
ER positive cells. 
•    Further exploration is required before assigning these differences only to endocrine 
sensitivity, or ER positive and ER negative BC. 
 
5.2 PAPER IV  
•    The gene expression differences between ER-positive and ER-negative BC seems 
mainly to be related to endocrine sensitivity and not metastatic potential.  
•    ER negativity may also be correlated with an increased tumor growth rate. 
•    The prognostic value of ER content is apparent only with endocrine treatment; 
therefore, it is mainly a predictive factor.  
 
5.3 PAPER V 
•    Current clinical use of IHC for determination of ER status is at least as good as the 
validated cytosol methods. 
•    The concordance between cytosol assays and IHC assay for determination of ER is 
high. 
 
5.4 PAPER II AND III 
•    Traditional tumor collection, storage and processing are inappropriate and affect 
mRNA quality and integrity. 
•    Gene expression shows heterogeneity both in normal and breast cancer tissue. 
•    Housekeeping genes express differently and are not proper as reference for 
normalization of cDNA microarray. 
•    It is possible that normalization to the number of cells (mg tissue) or amount DNA 
is more appropriate than normalization to total RNA. 
•    Results from microarray studies should be interpreted with caution and the potential 
of such studies as complementary to conventional factors needs further validation. 
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